Cavan M. Redmond - 24 Jun 2022 Form 4 Insider Report for Oncocyte Corp (OCX)

Reporting relationship: Director
Issuer ticker: OCX
Reported as of: 24 Jun 2022
Net transaction value: $0
SEC form: 4
Accepted by SEC: 19 Jul 2022, 16:05:42 UTC
Prior SEC filing: 16 Mar 2022
Source filing: View source filing
Reporting owner signature: /s/ Cavan M. Redmond

Key filing fact

Cavan M. Redmond filed Form 4 for Oncocyte Corp (OCX) on 19 Jul 2022.

Key facts

This page summarizes Cavan M. Redmond's Form 4 filing for Oncocyte Corp (OCX).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 19 Jul 2022, 16:05.

Change

Previous filing in this sequence was filed on 16 Mar 2022.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

OCX transaction

Common Stock, no par value

Options Exercise

Transaction value: $0
Shares: +10,000
Change %: +9%
Price: $0.000000
Shares after: 120,863
Date: 24 Jun 2022
Ownership: Direct

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

OCX transaction Derivative

Restricted Stock Units

Options Exercise

Transaction value: $0
Shares: -10,000
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 24 Jun 2022
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 10,000
Exercise price: $0.000000
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The Restricted Stock Units vested on June 24, 2022.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. to update or revoke optional consent for future visits. For more information, see our Privacy Policy .